US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

iShares MSCI Pacific ex Japan ETF

45.56

+0.17000.37%

Volume:63.87K

Turnover:2.90M

Market Cap:1.90B

PE:7.37

High:45.60

Open:45.50

Low:45.22

Close:45.39

Loading ...

Overview Company News Filings

F5 Strengthens Security Capabilities in the F5 Application Delivery and Security Platform

CarMax Reports Fourth Quarter and Fiscal Year 2025 Results

Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Health Check: Ansell gloves up for Trump tariff threat

Clinuvel Advances SCENESSE® Use for Adolescent EPP Treatment

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

BUZZ-Disc Medicine slips on planned stock sale

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Press Release: Aura Minerals Acquires Shares of Bluestone

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

CarMax Reports Third Quarter Fiscal Year 2025 Results

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

CrowdStrike Reports Third Quarter Fiscal Year 2025 Financial Results

Clinuvel in Talks with European Regulators Over Dosage Expansion for Metabolic Disorder Drug

MT Newswires Live

Press Release: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","market":"US","secType":"STK","nameCN":"iShares MSCI Pacific ex Japan ETF","latestPrice":45.56,"timestamp":1746027605379,"preClose":45.39,"halted":0,"volume":63868,"delay":0,"floatShares":41700000,"shares":41700000,"eps":6.184397,"marketStatus":"Trading","change":0.17,"latestTime":"04-30 11:41:10 EDT","open":45.5,"high":45.6,"low":45.22,"amount":2901734.0044,"amplitude":0.008372,"askPrice":45.56,"askSize":100,"bidPrice":45.55,"bidSize":100,"shortable":3,"etf":1,"ttmEps":6.184397,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":45.39,"sharesOutstanding":41700000,"nav":45.323488,"aum":1889989449.6,"dividendRate":0.036633,"bidAskSpread":0.000316,"preHourTrading":{"tag":"盘前","latestPrice":45.69,"preClose":45.39,"latestTime":"07:54 EDT","volume":600,"amount":27423.600000000002,"timestamp":1746014064429},"postHourTrading":{"tag":"盘后","latestPrice":45.41,"preClose":45.39,"latestTime":"16:05 EDT","volume":403,"amount":18302.17,"timestamp":1745957111499},"volumeRatio":0.638775,"impliedVol":0.0682,"impliedVolPercentile":0.528},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","floatShares":41700000,"roa":"2.21%","roe":"14.00%","lyrEps":6.184397,"volumeRatio":0.638775,"shares":41700000,"dividePrice":1.669,"high":45.6,"amplitude":0.008372,"preClose":45.39,"low":45.22,"week52Low":38.44,"pbRate":"0.96","psRate":"24.65","week52High":49.29,"institutionHeld":0,"latestPrice":45.56,"eps":6.184397,"divideRate":0.036633,"volume":63868,"delay":0,"ttmEps":6.184397,"open":45.5,"prevYearClose":43.81,"prevWeekClose":45.38,"prevMonthClose":44.1,"prevQuarterClose":44.1,"fiveDayClose":44.54,"twentyDayClose":44.6,"sixtyDayClose":44.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529278372","title":"F5 Strengthens Security Capabilities in the F5 Application Delivery and Security Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2529278372","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529278372?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Enhancements include cloud-native protection, web application scanning for LLM vulnerabilities, expanded API discovery tools, and enhanced client-side detection. F5’s Application Delivery and Security Platform named to 2025 Vendor Vision Report from analyst firm EMA; singled out for robust AI-driven security architecture and API protection capabilities. F5’s 2025 State of Application Strategy Report reveals expanded AI and API sprawl significantly impacts enterprise cybersecurity strategies. SEATTLE, April 22, 2025----F5 , the global leader in delivering and securing every app and API, today unveiled broad cybersecurity enhancements to the F5 Application Delivery and Security Platform  that significantly improve organizations’ ability to identify and remediate vulnerabilities and threats to AI and other modern applications. These new enhancements enable enterprises to strengthen security for business-critical applications in an increasingly risky threat landscape. The F5 ADSP is the in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/f5-strengthens-security-capabilities-f5-110000140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4596","LU2506951958.HKD","BK4532","EPP","LU0823417653.USD","BK4585","FFIV","BK4588","LU2506951875.HKD","LU2506952170.USD","LU0823417737.USD","STRK","LU0950375773.USD","BK4600","BK4516","BK4023","BK4582","LU2506952097.USD","BK4020","BK4595"],"gpt_icon":1},{"id":"2526552787","title":"CarMax Reports Fourth Quarter and Fiscal Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2526552787","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526552787?lang=en_us&edition=fundamental","pubTime":"2025-04-10 18:50","pubTimestamp":1744282200,"startTime":"0","endTime":"0","summary":"Achieved over 80% earnings growth in the fourth quarter driven by gains across the business. RICHMOND, Va., April 10, 2025----CarMax, Inc.  today reported results for the fourth quarter and fiscal year ended February 28, 2025.Retail used unit sales increased 6.2% and comparable store used unit sales increased 5.1%; wholesale units increased 3.1%.CarMax’s share of the nationwide age 0-10 year old used vehicle market remained at 3.7% in calendar year 2024. Accelerating gains in the back half of the year, reflecting the positive momentum across the business, offset losses in the first half of the year.Gross profit per retail used unit of $2,322, up $71 per unit and achieving a fourth quarter record. Gross profit per wholesale unit of $1,045, historically strong, down $75 per unit. Extended Protection Plans  margin per retail unit of $580, an increase of $10 per unit. Service margin loss of $4 per retail unit, an improvement of $257 per retail unit. 223,000 vehicles were purchased from con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carmax-reports-fourth-quarter-fiscal-105000035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KMX","EPP","BK4585","BK4582","BK4214","BK4588","CAF"],"gpt_icon":0},{"id":"2524127657","title":"Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much","url":"https://stock-news.laohu8.com/highlight/detail?id=2524127657","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524127657?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:00","pubTimestamp":1743537645,"startTime":"0","endTime":"0","summary":"Some investors contend Clinuvel’s mountain of $200 million of cash is excessive and amounts to a ‘lazy’ balance sheet. The company argues the cash buffer protects it against unexpected adversities and – in any event – every cent will be needed for clinical trials. Clinuvel highlights the divide between the sector’s cash have-nots and have-lots. Corporate investor briefings are normally civil affairs, but in the case of skin disorders specialist Clinuvel Pharmaceuticals  a recent powwow turned tetchy for a most unusual reason.The point of contention?","market":"nz","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-77130653-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-77130653-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/biocurious-while-other-biotechs-scratch-around-for-cash-clinuvel-is-accused-of-having-too-much/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["EPP","BK4582"],"gpt_icon":0},{"id":"2516692071","title":"Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692071","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692071?lang=en_us&edition=fundamental","pubTime":"2025-03-04 10:17","pubTimestamp":1741054620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, March  03, 2025  (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036144/0/en/Clinuvel-Introduces-Groundbreaking-Vitiligo-Program-at-the-World-s-Biggest-Dermatology-Meeting-AAD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPP","BK4582"],"gpt_icon":0},{"id":"2514791801","title":"Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514791801","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514791801?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"-- Targeting NDA submission for bitopertin in erythropoietic protoporphyria.  in H2 2025 through accelerated approval pathway; on track to. -- Positive update from Phase 1b trial of DISC-0974 in patients with anemia. of myelofibrosis  presented at ASH 2024; initial data from ongoing. -- Positive data from initial cohorts of ongoing Phase 1b study of DISC-0974. in patients with anemia of non-dialysis-dependent chronic kidney disease.  presented at ASN Kidney Week 2024; initial data from multiple. -- Presented first-in-human SAD/MAD data from Phase 1 trial of DISC-3405. demonstrating proof-of-mechanism; a Phase 2 study in polycythemia vera. -- Strong financial position ending 2024 with $490 million in cash, cash. equivalents, and marketable securities, further strengthened by the net. proceeds of our public offering in January 2025, expected to fund. WATERTOWN, Mass., Feb. 27, 2025  -- Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRON","EPP","BK4582"],"gpt_icon":0},{"id":"2510600654","title":"Health Check: Ansell gloves up for Trump tariff threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2510600654","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510600654?lang=en_us&edition=fundamental","pubTime":"2025-02-10 10:48","pubTimestamp":1739155692,"startTime":"0","endTime":"0","summary":"Ansell is expanding its manufacturing to be less reliant on China. Mayne Pharma pre-announces a strong first-half earnings recovery. Alterity Therapeutics raises $40 million on the back of encouraging trial","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1221546666-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1221546666-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-ansell-gloves-up-for-trump-tariff-threat/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["EPP","LU1923622291.USD","LU2125909759.SGD","LU2211815571.USD","LU1815336091.USD","MSA","LU0757428866.USD","LU2125909916.SGD","LU0053671581.USD","LU0728928796.USD","BK4582","BK4143"],"gpt_icon":0},{"id":"2510073993","title":"Clinuvel Advances SCENESSE® Use for Adolescent EPP Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2510073993","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510073993?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:17","pubTimestamp":1739143049,"startTime":"0","endTime":"0","summary":"An announcement from Clinuvel Pharmaceuticals Limited ( ($AU:CUV) ) is now available. Clinuvel has announced preliminary results from its study on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-advances-scenesse-use-for-adolescent-epp-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-advances-scenesse-use-for-adolescent-epp-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4582","EPP"],"gpt_icon":0},{"id":"2505033023","title":"Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2505033023","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505033023?lang=en_us&edition=fundamental","pubTime":"2025-01-23 10:35","pubTimestamp":1737599700,"startTime":"0","endTime":"0","summary":"Jefferies, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering. BMO Capital Markets, LifeSci Capital, Wedbush PacGrow and H.C. Wainwright & Co. are acting as co-managers for the offering.The securities described above are being offered by Disc pursuant to an automatic shelf registration statement on Form S-3  that was previously filed with the Securities and Exchange Commission  on August 8, 2024. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New Yo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/disc-medicine-announces-pricing-225-023500480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4582","IRON","EPP","BK4585","XLP","BK4588"],"gpt_icon":0},{"id":"2505772835","title":"BUZZ-Disc Medicine slips on planned stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2505772835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505772835?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:51","pubTimestamp":1737553897,"startTime":"0","endTime":"0","summary":"**  Disc Medicine's    shares down 1.9% to $59.35 premarket as biopharma firm looks to raise equity   ** Watertown, Massachusetts-based firm late Tues  $200 mln offering consisting of stock and pre-funded warrants   ** Co plans to use net offering proceeds to fund research and clinical development of its product candidates, to support potential commercialization of its treatment for erythropoietic protoporphyria , a    rare disease that causes painful sensitivity to light   ** IRON shares on Tues rose nearly 4% to close at $60.52 after co received  from US FDA for    ** Jefferies, Leerink, Stifel and Cantor jt bookrunners for the equity offering   ** Through Tues, IRON shares down 4.5% to begin 2025. Stock's 1-yr high is $77.60  and 1-yr low is $25.60  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","EPP","BK4582","JEF","IRON"],"gpt_icon":0},{"id":"2505784521","title":"Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2505784521","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505784521?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:01","pubTimestamp":1737493260,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 21, 2025  -- Disc Medicine, Inc.  , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has commenced an underwritten offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Disc intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the proposed offering are being offered by Disc. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Jefferies, Leerink P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/disc-medicine-announces-proposed-public-210100046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","EPP","XLP","BK4582","BK4585","IRON"],"gpt_icon":0},{"id":"2505224542","title":"Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2505224542","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505224542?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:45","pubTimestamp":1737463500,"startTime":"0","endTime":"0","summary":"Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on exist","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/21/3012551/0/en/Disc-Medicine-Announces-Successful-Type-C-Meeting-with-FDA-for-Bitopertin-in-Erythropoietic-Protoporphyria-EPP-and-Shares-Plans-for-NDA-Submission.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4582","XLP","BK4139","EPP","IRON","BK4588"],"gpt_icon":0},{"id":"2505573762","title":"Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505573762","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505573762?lang=en_us&edition=fundamental","pubTime":"2025-01-21 08:00","pubTimestamp":1737417600,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan.  20, 2025  (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of nove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/21/3012287/0/en/Disc-Medicine-to-Host-Conference-Call-on-Type-C-Meeting-for-Bitopertin-in-Erythropoietic-Protoporphyria-EPP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4585","BK4181","BK4218","IRON","BK4139","XLP","EPP","BK4582","BK4588"],"gpt_icon":0},{"id":"2503368690","title":"Press Release: Aura Minerals Acquires Shares of Bluestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2503368690","media":"Dow Jones","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503368690?lang=en_us&edition=fundamental","pubTime":"2025-01-15 04:22","pubTimestamp":1736886120,"startTime":"0","endTime":"0","summary":"ROAD TOWN, British Virgin Islands, Jan. 14, 2025 /CNW/ - Aura Minerals Inc.   , announces that in connection with the completion of its previously announced plan of arrangement and acquisition of Bluestone Resources Inc. , Aura has acquired 152,494,962 common shares of Bluestone, being all of their issued and outstanding common shares.Under the terms of the Arrangement, Aura acquired all of the issued and outstanding Common Shares from the former shareholders of Bluestone by payment of C$26,255,313.33 in cash and the issuance 1,007,186 Aura shares. Aura also issued contingent consideration in the form of 146,519,452 contingent value rights  providing each holder thereof with the potential to receive up to C$0.2120 for each CVR held, payable in three equal annual installments, contingent upon the occurrence of certain milestone events.Prior to the completion of the Arrangement, Aura owned a total of 5,975,510 Common Shares of Bluestone. Accordingly, the acquisition of the Common Shares ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","BK4582","EPP","MTX"],"gpt_icon":0},{"id":"2502861204","title":"Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502861204","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502861204?lang=en_us&edition=fundamental","pubTime":"2025-01-10 22:00","pubTimestamp":1736517600,"startTime":"0","endTime":"0","summary":"In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007729/0/en/Disc-Medicine-Highlights-Recent-Achievements-Across-Hematology-Portfolio-and-Key-Business-Objectives-and-Milestones-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4113","BK4139","EPP","MF","BK4582","IRON","BK4563","BK4526"],"gpt_icon":0},{"id":"2492124582","title":"CarMax Reports Third Quarter Fiscal Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2492124582","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492124582?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:50","pubTimestamp":1734609000,"startTime":"0","endTime":"0","summary":"Achieved over 50% earnings growth driven by gains across the business. RICHMOND, Va., December 19, 2024----CarMax, Inc.  today reported results for the third quarter ended November 30, 2024.Retail used unit sales increased 5.4% and comparable store used unit sales increased 4.3%; wholesale units increased 6.3%.Total gross profit of $677.6 million increased 10.6% driven by unit volumes and strong unit margin performance.Gross profit per retail used unit of $2,306, in line with the prior year’s third quarter. Gross profit per wholesale unit of $1,015, up $54 per unit. 237,000 vehicles were purchased from consumers, up 4.1%. Total retail used vehicle unit sales increased 5.4% to 184,243 compared to the prior year’s third quarter. Comparable store used unit sales increased 4.3% from the prior year’s third quarter. Total retail used vehicle revenues increased 1.2% compared with the prior year’s third quarter, driven by the increase in retail used units sold, partially offset by the decrease","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AOOmQMKWmq_UleiTV3UOEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/342742ac1e8b214344643ec592226d73","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AOOmQMKWmq_UleiTV3UOEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/342742ac1e8b214344643ec592226d73"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carmax-reports-third-quarter-fiscal-115000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KMX","BK4588","BK4214","EPP","CAF","BK4582","BK4585"],"gpt_icon":0},{"id":"2490083397","title":"Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490083397","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490083397?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993966/0/en/Disc-Medicine-Presents-Positive-Clinical-and-Translational-Data-Across-Portfolio-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","IRON","BK4109","BK4563","MF","EPP","BK4117","BK4526","ASH","BK4107","IBD","BK4539","BK4582","BK4113","LU2463526074.USD","BK4087","BK4139","DSS"],"gpt_icon":0},{"id":"2486834226","title":"CrowdStrike Reports Third Quarter Fiscal Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2486834226","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486834226?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:05","pubTimestamp":1732655100,"startTime":"0","endTime":"0","summary":"Surpasses $4 billion ending ARR milestone, grows 27% year-over-year to reach $4.02 billion. Exceeds $1 billion quarterly total revenue milestone, grows 29% year-over-year to reach $1.01 billion. Delivers cash flow from operations of $326 million and free cash flow of $231 million, achieving a free cash flow rule of 51. AUSTIN, Texas, November 26, 2024----CrowdStrike Holdings, Inc.  today announced financial results for the third quarter fiscal year 2025, ended October 31, 2024.Net Income/Loss Attributable to CrowdStrike: GAAP net loss attributable to CrowdStrike was $16.8 million, compared to income of $26.7 million in the third quarter of fiscal 2024. GAAP net loss per share attributable to CrowdStrike, diluted, was $0.07, compared to income of $0.11 in the third quarter of fiscal 2024. Non-GAAP net income attributable to CrowdStrike was $234.3 million, compared to $199.2 million in the thi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GxvKIYRIu3HelZSU3P3YXg--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/39f7efdf8db4a1f2fcb191941ced71e5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GxvKIYRIu3HelZSU3P3YXg--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/39f7efdf8db4a1f2fcb191941ced71e5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crowdstrike-reports-third-quarter-fiscal-210500328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","BK4532","BK4598","ARR","LU1720051108.HKD","LU1974910355.USD","BK4551","LU1951200564.SGD","LU2286300806.USD","EPP","LU1917777945.USD","IE00BZ9MQY76.HKD","LU1548497426.USD","CRWD","BK4560","LU2264538146.SGD","LU2272731782.SGD","BK4585","IE00B894F039.SGD","BK4588","LU1064131342.USD","LU2357305700.SGD","LU2433249047.HKD","LU1720051017.SGD","BK4582","BK4097","LU1992135472.HKD","LU2125909247.SGD","LU2125909593.SGD","LU1923623000.USD","LU1923622291.USD","IE00B19Z9P08.USD","LU1951198990.SGD","LU2272731600.USD","IE00B19Z9Z06.USD","BK4110","LU1923622614.USD","LU2125909759.SGD","LU2211815571.USD","LU1992135399.USD","BK4528","LU1988902786.USD","LU2023250504.SGD","LU2125909916.SGD"],"gpt_icon":1},{"id":"2484618080","title":"Clinuvel in Talks with European Regulators Over Dosage Expansion for Metabolic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618080","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484618080?lang=en_us&edition=fundamental","pubTime":"2024-11-20 09:52","pubTimestamp":1732067538,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said it is in talks with the European Medicines Agency  to increase the recommended maximum dose of its drug Scenesse for adult patients with erythropoietic protoporphyria , according to a Wednesday filing with the Australian bourse.EPP is an inherited condition characterized by extreme photosensitivity and could lead to liver disease.The EMA's Pharmacovigilance Risk Assessment Committee will decide whether to maintain the existing drug label or expand it to up to six times per year, the filing said.The outcome is expected by the first quarter of 2025, according to the filing.Clinuvel Pharmaceuticals' shares were down more than 2% in recent Wednesday trade.Price : $13.30, Change: $-0.32, Percent Change: -2.39%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","LU0426417589.USD","EPP","BK4582","LU0994945656.USD","LU0426412945.USD","BK4125","BK7508","LU0345774631.USD","LU2238339852.HKD","CUV.AU","LU1043141123.HKD","BK7067"],"gpt_icon":0},{"id":"2482770925","title":"Press Release: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482770925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482770925?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"-- Completed a successful end of Phase 2 meeting with the FDA for bitopertin. in erythropoietic protoporphyria , reaching alignment on all. proposed study parameters with the potential for accelerated approval. -- Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in. anemia at the American Society of Nephrology  Kidney Week 2024. \"This is an exciting time for Disc as we have made significant progress in advancing our pipeline in recent months and remain keenly focused on execution as we prepare for multiple upcoming catalysts. We now have clarity on the path forward for bitopertin in EPP, with the potential for accelerated approval, and added to the data set supporting the potential of DISC-0974 in treating anemias of inflammation with positive SAD data in NDD-CKD,\" said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. \"Additionally, with the recent completion of a debt financing with Hercules Capital, we have further solidified our strong financ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4526","EPP","TSAT","BK4582","BK4109","BK4539","IBD","ASH","BK4563","LU2463526074.USD","BK4089","MF","BK4139","BK4113"],"gpt_icon":0},{"id":"2481108335","title":"Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481108335","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481108335?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:30","pubTimestamp":1731072600,"startTime":"0","endTime":"0","summary":"-- Facility significantly increases future financial and operational. -- Up to $200M available, with $30 million drawn at close and additional $80. million available at Disc's sole discretion through second-half 2026. recently announced potential accelerated approval pathway for bitopertin. \"Hercules is pleased to partner with Disc in the further development of their hematology pipeline,\" said Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. \"We are committed to financing promising life sciences companies to help them achieve their ambitious goals, and we are excited to collaborate with the Disc team ahead of numerous milestones and support them in their next phase of growth.\". The loan facility consists of up to four tranches, three of which can be drawn at Disc's option and each maturing in November 2029. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4582","BK4135","EPP","BK4139","BK4113","BK4526","MF","BK4539","IRON","HTGC"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPP\",params:#limit:5,,,undefined,":[{"date":"2024-12-17","symbol":"EPP","amount":0.96746,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"EPP","amount":0.70131,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2023-12-20","symbol":"EPP","amount":0.966028,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"EPP","amount":0.814552,"announcedDate":"2023-06-06","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"},{"market":"US","date":"2022-12-13","symbol":"EPP","amount":0.70879,"defaultRemindTime":1670941800000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2022-12-19","payableDate":"2022-12-14","currency":"USD","type":"dividend","dateTimestamp":1670907600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPP\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-25","recordDate":"2015-06-29","paymentDate":"2015-07-01","value":0.952237,"currency":"USD"},{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":0.927279,"currency":"USD"},{"executeDate":"2016-06-22","recordDate":"2016-06-24","paymentDate":"2016-06-28","value":0.661333,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-28","value":0.90607,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.756156,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPP\",market:\"US\",delay:false,,,undefined,":{}}}